[Pharmacological and clinical profile of Onasemnogene Aveparvovec, the first gene therapy for spinal muscular atrophy (SMA)].

Atsumi, Ayaka; Yoneda, Tomohiro; Tsuchida, Ken; Kagawa, Yusuke; Tominaga, Shunsuke; Kawase, Kazuho; Kikuchi, Nobutaka

Atsumi, Ayaka; Yoneda, Tomohiro; Tsuchida, Ken; Kagawa, Yusuke; Tominaga, Shunsuke; Kawase, Kazuho; Kikuchi, Nobutaka.

Affiliation

Atsumi A; Medical department of Gene Therapies business Unit, Novartis Pharma K.K.
Yoneda T; Global Drug Development Division, Novartis Pharma K.K.
Tsuchida K; Global Drug Development Division, Novartis Pharma K.K.
Kagawa Y; Global Drug Development Division, Novartis Pharma K.K.
Tominaga S; Global Drug Development Division, Novartis Pharma K.K.
Kawase K; Medical department of Gene Therapies business Unit, Novartis Pharma K.K.
Kikuchi N; Medical department of Gene Therapies business Unit, Novartis Pharma K.K.

Nihon Yakurigaku Zasshi ; 157(1): 53-61, 2022.

Article de Ja | MEDLINE | ID: mdl-34980814

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Amyotrophie spinale / Amyotrophies spinales infantiles Type d'étude: Prognostic_studies Limites: Animals / Humans Langue: Ja Journal: Nihon Yakurigaku Zasshi Année: 2022 Type de document: Article Pays de publication: Japon

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google